Press Releases

CRANBURY, N.J., Dec. 2, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that Dr. Carl Spana, the Company’s chief executive officer, will participate in a “Fireside Chat” at the 25th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on December 4, 2013. The conference will be held at the New York Palace […]

CRANBURY, N.J., Nov. 14, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2013.  Recent Highlights Bremelanotide development for Female Sexual Dysfunction (FSD): Successful completion

CRANBURY, N.J., Nov. 13, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has entered into an option agreement for an exclusive license to bremelanotide for female sexual dysfunction indications in selected

CRANBURY, N.J., Nov. 12, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office today issued two new patents to Palatin.  Both patents support Palatin’s program developing

CRANBURY, N.J., Nov. 11, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2014 operating results on Thursday, November 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14,

CRANBURY, N.J., Oct. 28, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe administration. Bioequivalence was achieved in this clinical trial. Palatin used pre-filled syringes in its Phase 2 clinical trials, but will

CRANBURY, N.J., Oct. 4, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced that it will be presenting at the 12th Annual BIO Investor Forum on Tuesday, October 8, 2013 at 3:30 p.m. Pacific Time.  Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum will take place October 8-9 at The

CRANBURY, N.J., Sept. 25, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its fourth quarter, fiscal year 2013 operating results on Monday, September 30, 2013 after the close of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on October

CRANBURY, N.J., May 14, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced financial results for the third quarter ended March 31, 2013. The Company also summarized end-of-Phase 2 discussions with the U.S.

CRANBURY, N.J., May 8, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its third quarter, fiscal year 2013 financial results on Tuesday, May 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 14,